Categories: EHRNews

Acuitive Technologies introduces Citregraft, a unique bone graft substitute designed to bind proteins and enhance regeneration

ALLENDALE, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) — Acuitive Technologies® commercializes Citregraft™, with its first use in a surgical case, performed on November 4th, 2025.

Bone graft substitutes are used to repair defects from trauma, infection, tumor removal, and reconstructive surgery. However, poor handling, low biological activity, variable resorption rate, and inadequate integration limit their effectiveness.

Leveraging the benefits of citrate in bone anatomy and physiology, Acuitive Technologies developed Citregen®, a citrate-based polymer technology that mimics natural bone chemistry and supplies the energy needed for regeneration. Exclusively made with Citregen and bioactive glass, Citregraft is a highly porous and bioactive synthetic bone graft substitute designed to interact with proteins to regenerate bony voids within the skeletal system.

Citregraft benefits include:

  •  Bioactive formulation to improve graft integration
  •  Easily morselized to fill and hold its position within irregular defects
  •  Absorbs 5 times its weight in fluids
  •  Synergizes with bone marrow aspirate (BMA) to bind proteins
  • Citrate increases cell energy for tissue regeneration

Citregraft was easily morselized to fill my tibial harvest site during BPTB ACL reconstruction. After soaking it in saline, it readily absorbed blood and growth factors from the harvest site and conformed perfectly to the defect,” said Robin Gehrmann, MD.

Citregraft overcomes the limitations of conventional bone graft substitutes by improving handling, liquid uptake, and protein binding. Its demonstrated bioactivity and ability to bind proteins establish Citregraft as a viable option for surgeons seeking innovative solutions for bone repair and regeneration.

Media Contact
Thomas McCarthy
Acuitive Technologies, Inc.
tmccarthy@acuitivetech.com
https://www.acuitivetech.com/

Data on file, TM251008, at Acuitive Technologies Inc., Allendale, NJ, USA

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/233ecf43-c685-4d77-ba95-b1a49b14eecb

Staff

Recent Posts

Atropos Health Expands Oncology Precision Medicine Capabilities with Publication of New AI Algorithms for Rare Disease and Integration of ASCO Guidelines

Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…

55 minutes ago

USF and Old Dominion to Play in the 2025 StaffDNA Cure Bowl

PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…

58 minutes ago

The Dot Corp Expands Services With New Promotional Products & Apparel Division

IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…

58 minutes ago

Vaniam Group Launches Predictive Pathways: A New Capability for Anticipating Market-Shaping Signals

CHICAGO, Dec. 5, 2025 /PRNewswire/ -- Vaniam Group™, a category leader redefining medical communications, announced…

59 minutes ago

Biorep Technologies Announces First Successful Independent Research Use of the PRISM System in Islet Isolation

Results confirm reproducibility and research readiness for islet isolation of Biorep's next generation laboratory platform.MIAMI,…

59 minutes ago